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Abstract
Background: Severe falciparum malaria may be complicated by prolonged haemolysis and recurrent fever after
parasite clearance. However, their respective etiologies are unclear and challenging to diagnose. We report the first
case of severe falciparum malaria followed by prolonged haemolytic anaemia and rhinomaxillary mucormycosis in a
previously healthy adult male.
Case presentation: A 30-year old Bangladeshi man was admitted with severe falciparum malaria complicated by
hyperlactataemia and haemoglobinuria. Prior to admission he was treated with intravenous quinine and upon
admission received intravenous artesunate and empiric ceftriaxone. Thirty hours later the peripheral parasitaemia
cleared with resolution of fever and haemoglobinuria. Despite parasite clearance, on day 3 the patient developed
recurrent fever and acute haemolytic anaemia requiring seven blood transfusions over six days with no improvement
of his haemoglobin or haemoglobinuria. On day 10, he was treated with high-dose dexamethasone and meropenem
with discontinuation of the ceftriaxone. Two days later the haemoglobinuria resolved. Ceftriaxone-induced haemolysis
was the suspected final diagnosis. On day 16, the patient had progressively worsening right-sided facial pain and
swelling; a necrotic ulceration of the hard palate was observed. Rhinomaxillary mucormycosis was diagnosed
supported by microscopy findings. The patient initially responded to treatment with urgent surgical debridement,
itraconazole, followed by two weeks of amphotericin B deoxycholate, however was subsequently lost to follow up.
Conclusions: This case highlights the range of potential alternative aetiologies of acute, prolonged haemolysis and
recurrent fever following parasite clearance in severe falciparum malaria. It emphasizes the importance of a high
degree of suspicion for alternative causes of haemolysis in order to avoid unnecessary treatments, including blood
transfusion and steroids. It is critical to consider and identify common invasive bacterial and rare opportunistic
co-infections as a cause of fever in severe malaria patients remaining febrile after parasite clearance to promote
antimicrobial stewardship and prompt emergency care.
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Background
The mortality rate of adult severe malaria remains high
at between 10 % and 30 %. In surviving patients recovery
is usually complete, and neurological sequelae occur in
less than 1 % [1]. Rare complications following severe
falciparum malaria include acute, prolonged haemolytic
anaemia and invasive fungal infections [2, 3]. Prolonged
anaemia following parasite clearance in falciparum mal-
aria is multifactorial. Proposed mechanisms include
hypoproliferative erythropoiesis, ineffective erythropoi-
esis, red blood cell (RBC) membrane alteration with re-
duced survival, and continued peripheral haemolysis [2].
Broadly, the causes of ongoing haemolysis after parasite
clearance are complex and include: (1) immune-mediated,
secondary to parasite antigens, complement activation,
splenic retention, or drug-induced autoimmune haemoly-
sis (i.e. aryl-amino-alcohol containing antimalarials) [4–7],
and (2) non-immune mediated, secondary to rupture of
sequestered schizonts and uninfected RBCs and oxidative
stress [8, 9]. Recently, delayed onset haemolysis after fal-
ciparum malaria has been associated with parenteral arte-
sunate use in non-immune patients with high ring stage
admission parasitaemias [10–19]. Three patterns of post-
treatment anaemia following malaria have been proposed
namely, ‘rising’, ‘persistent’ and ‘post-artesunate delayed
haemolysis’ [20].
Invasive fungal infections complicating severe falcip-
arum malaria infections are rare, particularly mucormy-
cosis [21–27]. Zygomycetes can cause life-threatening
angioinvasive mucormycoses that present as rhinocereb-
ral, pulmonary, renal, gastrointestinal, cutaneous and/or
disseminated infection. Individuals with an immunocom-
promising condition or iron overload are particularly pre-
disposed to these acute-onset, rapidly progressive and
aggressive infections. The overall mortality is 44 %, how-
ever in the case of haematogenous disseminated disease
up to 94 % of patients have a fatal outcome [28]. Success-
ful management of mucormycosis requires prompt diag-
nosis, reversal of underlying immunosuppression, and
urgent surgical debridement together with anti-fungal
therapy. Only one case of disseminated mucormycosis
complicating severe falciparum malaria has been reported
[3]. We report the first case of rhino-maxillary mucormy-
cosis following Plasmodium falciparum infection compli-
cated by prolonged haemolysis after parasite clearance.
Case presentation
A 30-year-old previously well Bangladeshi male was ad-
mitted to a local tertiary care hospital with a 20-day his-
tory of fever, chills, rigors, headache, myalgias, and
anorexia. He had been suffering from nausea, vomiting,
diarrhoea, jaundice with scleral icterus and dark urine
for five days. One day prior to admission, he was diag-
nosed with malaria on thick smear at a private hospital,
however parasite density result was unavailable. There
he was treated with intravenous quinine (750 mg 8-
hourly x five doses) and azithromycin, due to limited
availability of first line therapy of artesunate, before be-
ing referred for further management.
Past medical history was significant for three prior
malaria infections. His most recent episode of suspected
vivax malaria was 30 days prior to admission, which was
partially treated with an incomplete course of chloro-
quine. He had no history of jaundice, liver disease, trans-
fusions, malignancy, or autoimmune disease. There was
no family history of jaundice or iron treatments. He did
not take any regular or traditional medicines. There was
no history of betel nut consumption.
On admission, he had a temperature of 39.7 oC, Glas-
gow Coma Score (GCS) 15/15, blood pressure (BP) 127/
60 mmHg, heart rate (HR) 127 beats per minute, a re-
spiratory rate (RR) of 24 breaths per minute with oxygen
saturation (SaO2) of 93 % on room air, and body weight of
65 kg. He appeared unwell with pronounced scleral ic-
terus, black urine, hepatomegaly and splenomegaly (4 cm
and 5 cm below the costal margin, respectively). There
was no conjunctival suffusion or lymphadenopathy.
Admission peripheral blood smear confirmed a diag-
nosis of falciparum malaria (360 parasites/μl). Severity
criteria included hyperlactataemia (lactate 6.8 mmol/L),
hyperbilirubinaemia (total bilirubin 58 μmol/L), and 4+
haemoglobinuria (blackwater fever); hence the case was
classified as severe malaria (Table 1). He was promptly
treated with intravenous artesunate 120 mg, 2.4 mg/kg
body weight (Guilin Pharmaceuticals, China) at 0, 12, 24
and 48 h (four doses), in addition to empiric ceftriaxone
2,000 mg every 12 h, as per local hospital practice. After
30 h his peripheral parasites cleared with resolution of
the fever and haemoglobinuria, and he was switched to
oral artemether/lumefantrine (AL) combination 80/480 mg
(Novartis, Switzerland).
On the third day of admission he developed fever, confu-
sion, dyspnoea (RR 28, SaO2 90 %), tachycardia (HR 106),
hypotension (BP 100/80 mmHg), recurrent 4+ haemo-
globinuria with severe microcytic anaemia (haemoglobin
of 32 g/L) accompanied by elevated lactate dehydrogenase
and bilirubin, consistent with acute haemolytic anaemia
(Table 1, Fig. 1). Pre-transfusion peripheral blood smear
showed no schistocytes and reticulocytes of 2 % (reticulo-
cyte production index 0.15 (compared to RPI of 0.3 on day
3 in blackwater fever patients [29]). Direct antiglobulin test
(DAT; anti-IgG and anti-C3d) was negative and indirect
antiglobulin test (IAT) was positive. Glucose was normal.
Blood and urine bacterial cultures were negative. Glucose-
6-phosphate dehydrogenase testing and haemoglobin typ-
ing were not available. Human immunodeficiency virus,
syphilis, hepatitis A, hepatitis B and hepatitis C serology
were negative. Hepatitis B antigen was negative. He
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promptly received transfusion of three units matched
whole blood. Intravenous artesunate was substituted for
AL despite parasite clearance due to the notion that the re-
current fever must be due to malaria. In total, he received
seven doses of artesunate (total dose of 840 mg) and three
doses of AL (total dose of artemether 240 mg, and lume-
fantrine 1,440 mg). Empiric amikacin 500 mg, 7.5 mg/kg
8-hourly was added on day 6 to broaden antibacterial
coverage for potential multi-drug resistant gram-negative
bacteria given his ongoing fever despite negative blood and
urine cultures. The haemolysis continued for nine days
and he required a total of 10 transfusions (Fig. 1).
On day 10, bone marrow biopsy revealed gross hyper-
cellularity with erythroid hyperplasia and no evidence
of lymphoma, leukaemia, or haemophagocytic syn-
drome. Meropenem (500 mg 8-hourly) was empirically
substituted for amikacin and ceftriaxone given his renal
dysfunction to cover potential extended-spectrum β-
lactamase producers, and dexamethasone 5 mg 6-hourly
was initiated for suspected autoimmune haemolytic
Fig. 1 Haemoglobin, haematocrit (HCT) and mean corpuscular haemoglobin (MCH) profile during hospital admission. Arrows indicate timing of
one-unit whole blood transfusions. Asterisk indicates initial transfusion of 3 units
Table 1 Laboratory investigations
Parameter Day 0 Day 3 Day 4 Day 7 Day 10 Day 28/29 Normal Range
Haemoblobin (g/L) 107 32 31 36 34 68 140–180
Haematocrit (%) 28.6 10 8.4 10 – 20.4 47–54
Mean corpuscule volume (fL) 79.4 – 76.4 73.5 – 83 76–96
Platelets (x103/μl) 38 – 32 160 180 160 150–400
White blood cells (x103/μl) 8.4 3.2 3.2 4.5 8 3.8 4–10
Lactate (mmol/L) 6.8 3.6 – – – – 0.9–1.7
Creatinine (μmol/L) 185 177 159 133 265 133 35-124
Bicarbonate (mmol/L) 18.3 17.1 – 29.6 – 23.2 23–28
Base excess (mmol/L) −7 −8 – 0 – 0 (-2)–(+3)
Anion gap (mmol/L) 19 17 – 15 – – 10–20
Total bilirubin (μmol/L) 58 82 75 – – – 3–21
Indirect bilirubin (μmol/L) 34 – 53 – – – 2–14
Alanine aminotransferase (IU/L) 23 59 – – 1260 57 5–41
Alkaline phosphatase (IU/L) 66 – 74 – – – 44–147
Gamma-glutamyl transferase (IU/L) 18 – 13 – – – <55
Lactate dehydrogenase (IU/L) – – 2950 – – – 140–280
International normalization ratio – 1.3 – – 2.18 – 0.8–1.2
Partial thromboplastin time (seconds) – 15 – – 27 – <30
Erythrocyte sedimentation rate (mm)a – 155 – 147 160 61 0–10
aWestergren method
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anaemia. The haemoglobinuria resolved two days after
steroid treatment and ceftriaxone discontinuation. His
haemoglobin slowly recovered, reaching 76 g/L by day 20.
On day 16, he had ongoing fever with right-sided facial
pain and swelling. A large, 3 × 2 cm ulcer on the right
upper hard palate covered with yellow slough and an
area of necrosis was observed (Fig. 2a). The right maxil-
lary sinus was tender on palpation. He had pain with
right eye extra-ocular movements but no ocular dis-
charge, proptosis, pupil asymmetry, diplopia, or de-
creased visual acuity. There was no nasal or ear
involvement. A swab of the hard palate ulceration re-
vealed long, broad, aseptate hyphal elements displaying
90° branching consistent with Mucor, (Fig. 2b). Fungal
cultures failed to grow. MRI showed extensive right-
sided opacification and mucosal thickening of the maxil-
lary and ethmoid sinuses with no radiographic evidence
of orbital or cerebral extension (Fig. 3). He underwent
prompt surgical debridement of the oral ulcer and right
maxillary sinus. His steroids were discontinued and he
was started on oral itraconazole 100 mg 12-hourly until
first line treatment with amphotericin B became avail-
able nine days later. Intravenous amphotericin B deoxy-
cholate 50 mg daily, was continued for 14 days with
improvement of his facial swelling and oral ulceration.
The patient was pleased with his clinical improvement
and hospital care, however due to a family emergency in
his remote village he left hospital against medical advice
and could not attend follow up.
Conclusions
The mechanism of the haemolytic component of an-
aemia following parasite clearance in falciparum malaria
is poorly understood and challenging to differentiate.
This case does not completely conform to one of the
three patterns of post-treatment malaria anaemia as it
appeared bimodal within a short time period, where the
initial episode of haemolysis occurring while parasitae-
mic resolved by 30 h after artesunate treatment, and a
second episode of massive haemolysis began on day 3
with 75 % drop in haemoglobin that persisted for 10 days
requiring multiple transfusions. This case highlights that
drug-induced haemolysis may contribute. Several anti-
malarial drugs can cause haemolysis by differing mecha-
nisms including quinine, mefloquine, halofantrine, and
primaquine. Two possible culprit drugs in our case in-
clude quinine and ceftriaxone. Quinine was given prior
to admission, and blackwater fever (intravascular haem-
olysis with haemoglobinuria) was observed on his initial
presentation with P. falciparum parasitaemia. Quinine-
induced haemolytic anaemia is considered drug-dependent
and proposed to occur through an immune-complex
mechanism [30, 31], however since the acute haemolysis
began on day 3, by which time around 95 % of the drug
would have been eliminated [32], and the DAT was nega-
tive, quinine seems less likely to be the cause. Drug-
induced immune haemolytic anaemia (DIIHA) is rare but
the commonly cited incidence of 1 per million people is
likely an underestimate due to under-diagnosis [33]. In pa-
tients with DIIHA, ceftriaxone is the second most com-
mon antimicrobial cause after cefotetan [30, 33]. The
onset of ceftriaxone-induced DIIHA ranges from 30 min
to 34 days following exposure [30]. In this case, the nega-
tive DAT and positive IAT suggest the presence of an allo-
antibody or free autoantibody. The DAT is typically
positive in most cases of drug-induced haemolytic anaemia
but a negative DAT is possible if massive haemolysis oc-
curs before testing [33, 34]. A diagnosis of ceftriaxone-
induced DIIHA is supported in our case because the
haemoglobinuria stopped two days after discontinuing cef-
triaxone, however the haemoglobin was still recovering to
baseline 2 weeks post-ceftriaxone discontinuation. Steroids
Fig. 2 Oral ulceration. a Ulcer on right upper hard palate measuring
3x2cm, covered with yellow slough and a posterior area of necrosis.
The borders of the ulcer were undermined. b Light microscopy x100
image of wet mount from swab sample of hard palate ulceration
showing long, broad, aseptate hyphal elements displaying 90° branching
consistent with Mucor
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do not improve DIIHA, but were administered in this case
for potential autoimmune haemolytic anaemia [33]. Since
steroid was started at the same time that ceftriaxone was
stopped, establishing the cause of haemolysis is con-
founded. The diagnosis of ceftriaxone-induced haemolytic
anaemia could not be confirmed because specific ceftrix-
one- antibody testing was not available.
The differential diagnosis for acute onset haemolytic
anaemia with positive IAT and negative DAT following
parasite clearance includes alloantibody mediated from
previous transfusion, drug-induced haemolytic anaemia,
microangiopathic haemolytic anaemia, an intrinsic RBC
abnormality, or may be a non-specific finding [30, 33].
Delayed haemolytic transfusion reactions are generally
mild and the onset of haemolysis is usually 2 to 11 days
after subsequent transfusion. This diagnosis was unlikely
as there was no history of previous blood transfusion
and haemolysis started before the transfusions. Reports
of post artesunate delayed haemolysis typically occur in
hyperparasitaemic patients and manifest 7–14 days fol-
lowing the first dose of artesunate [19, 20]. This diagno-
sis is unlikely since this patient did not have a high
parasitaemia and haemolysis started three days after the
start of artesunate. The available blood results do not
support the diagnosis of a microangiopathic haemolytic
anaemia, intrinsic RBC abnormality or functional asple-
nia since there were no obvious red cell abnormalities or
Howell-Jolly bodies on peripheral blood smear.
Fever in severe malaria usually resolves by day 4 to 5
[35]. Thus, recurrent or prolonged fever after severe
malaria should prompt investigation into alternative
causes. We identified a necrotic oral ulcer, from which a
sample showed Mucor morphology on slide microscopy
(Fig. 2). While our diagnosis was not confirmed by cul-
ture, this is not a prerequisite for the diagnosis since
these organisms are difficult to grow and frequently cul-
tures yield no growth. While mucormycosis is frequently
fatal in immunocompromised hosts, such as those with
haematological malignancies and diabetes mellitus, cases
in patients without any immune impairment have been
reported [28, 36]. These infections manifest as localized
cutaneous or disseminated deep infections and are char-
acterised by necrotic lesions due to the angioinvasive be-
havior of these organisms. Rhinocerebral mucormycosis
is the most common clinical presentation of mucormy-
cosis, representing around 60 % of all cases [37]. This
category is further divided into 2 subtypes: the highly ag-
gressive, often fatal rhino-ocular-cerebral form and the
less fatal rhino-maxillary form. The latter subtype mani-
fests as necrosis of the palate due to angioinvasion and
thrombosis of the sphenopalatine and greater palatine
arteries [38, 39].
Invasive fungal infections are rarely reported in associ-
ation with severe malaria [22]. A recent review summa-
rized nine cases of invasive fungal infections complicating
falciparum malaria; 5 Aspergillus, 1 hyalohyphomycosis, 2
Cryptococcus, 1 Absidia, and 1 disseminated candidiasis
[21–27]. The immune suppression due to malaria infec-
tion itself may predispose individuals to invasive fungal in-
fection [3, 22]. Parasitic digestive vacuoles containing
Fig. 3 MRI brain. Opacification and mucosal thickening of the right maxillary and ethmoid sinuses. Left – T2 weighted image; right– T1 weighted image
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malaria pigment phagocytosed rapidly by polymorpho-
nuclear granulocytes can cause functional exhaustion,
which blunts microbicidal activity of granulocytes [40].
Neutrophil dysfunction might result from haemolysis-
induced haem oxygenase-1 induction [41]. High-dose ste-
roids may also have inhibited the polymorphonuclear
leukocyte response and decreased granulocyte phago-
cytosis. In this case, the iron overload state secondary
to massive haemolysis and multiple transfusions may
have promoted fungal growth [37, 42, 43]. All reported
Aspergillus and Absidia infections complicating severe
malaria have occurred in patients with marked haem-
olysis [3, 23, 24, 26].
In this case it was difficult to definitively exclude a
predisposing immunocompromising condition. However,
bone marrow biopsy did not suggest an underlying
haematologic malignancy, HIV serology was negative,
and random glucose was normal in the setting of acute
illness, although haemoglobin A1C testing was unavail-
able to definitely rule out diabetes. It is likely that mal-
aria related immune suppression augmented by the
administration of steroids and multiple blood transfu-
sions with massive haemolysis (iron overload) contrib-
uted. The initial low parasitaemia is consistent with
post-treatment presentation and the severity criteria
present on admission are consistent with a delayed time
to recovery in severe malaria patients from low trans-
mission settings [1]. Concomitant bacterial infection was
not definitively excluded since admission blood culture
results were not available, however the day 0 white
blood cell count was normal. The kidney and liver dys-
function that developed when mucormycosis was diag-
nosed has several explanations but is unlikely related to
disseminated Mucor. More plausibly, the kidney injury
was due to high cell-free haemoglobin generated during
massive haemolysis, ischaemia, or nephrotoxic drugs (i.e.
amikacin). The liver dysfunction was likely due to is-
chaemia during hypotensive episodes.
In addition to urgent surgical debridement, the recom-
mended first line anti-fungal therapy for the treatment
for mucormycosis is amphotericin B deoxycholate or li-
posomal amphotericin B. Unfortunately, the availability
of these medications is often inadequate in resource-
limited settings. In this case, surgical debridement was
successful but itraconazole was the only available anti-
fungal with activity against Mucorales. Although the
patient follow up was truncated there was a favorable in-
hospital clinical response to itraconazole, which is in
keeping with other reports of successful treatment with
itraconazole monotherapy [44, 45].
The oral ulceration differential diagnosis includes
squamous cell carcinoma, deep fungal infection, tertiary
syphilis and acute necrotizing ulcerative gingivitis [46–
49]. In our case, the acute course of disease goes against
a diagnosis of squamous cell cancer. Negative non-
treponemal syphilis serology and an atypical presenta-
tion exclude tertiary syphilis. The sinus involvement and
presence of fungal hyphae makes acute necrotizing gin-
givitis unlikely. Most cases of rhinocerebral mucormyco-
sis involve both sides of the palate, however hemi-palatal
involvement has been reported [38, 39]. This patient
presented with typical symptoms of rhinomaxillary
mucormycosis including fever, headache, lethargy, pain
and swelling of the maxillary sinus. Microscopy differen-
tiated Mucor from aspergillus as broad, aseptate hyphae
at 90° angles were observed.
This case illustrates that both prolonged haemolysis
and recurrent fever occurring after parasite clearance in
falciparum malaria are challenging to diagnose. A sys-
tematic approach to the differential diagnoses is vital as
management can be critically different. The potential
diagnosis of ceftriaxone-induced haemolytic anaemia is
important as this drug is widely used empirically. Al-
though the incidence of ceftriaxone-induced haemolytic
anaemia is low, this diagnosis should be considered and
ceftriaxone discontinued to prevent unnecessary blood
transfusions, steroid treatment and mortality [30, 33].
Steroids are not recommended as treatment for severe
malaria because steroids increase gastrointestinal bleed-
ing, convulsions, and prolong coma [50, 51]. Investigat-
ing fever in resource-limited setting is challenging, as
microbiologic diagnoses are frequently not possible.
However, delayed evaluation of recurrent fever after
parasite clearance may lead to unnecessary empirical
anti-malarial and anti-bacterial use, which has important
consequences on the individual and global level. Al-
though invasive fungal infections rarely complicate se-
vere malaria, early diagnosis and treatment with surgical
debridement plus anti-fungals are essential to improve
patient outcomes. Empiric overuse of antimicrobials
contribute to anti-microbial resistant organisms, which
is a global public health concern in this era of reduced
research and development into novel antimicrobial ther-
apeutics. To combat this pressing issue, improved mi-
crobial diagnostics are urgently needed in resource-
limited settings.
Learning points
 Potentially reversible drug-induced haemolytic
anaemia may rarely complicate severe malaria
following parasite clearance but needs to be
considered to avoid unnecessary blood transfusion
or steroid treatment.
 Ceftriaxone is a commonly used empiric antibiotic,
however rarely (<0.1 % incidence) it may cause life
threatening haemolysis. This diagnosis must be
considered early as stopping the drug may be the
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only treatment needed and the haematologic
response can be rapid.
 Caution must be exercised when considering steroid
use in severe falciparum malaria, since no benefit
has been shown, whereas there are potential adverse
effects, such as in the present case where it may
contribute to immunosuppression facilitating fungal
infection.
 Recurrent fever after parasite clearance should
prompt a thorough septic evaluation to avoid delays
in diagnosis and overuse of empiric antimicrobials.
 Invasive fungal infections are a rare complication
(<0.1 % incidence) of severe malaria but should be
considered in individuals with prolonged fever after
parasite clearance.
 Mucormycosis infection is a medical emergency
requiring urgent surgical and medical management
and carries high morbidity and mortality.
Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
Abbreviations
RBC: red blood cell; GCS: Glasgow coma score; BP: blood pressure; HR: heart
rate; RR: respiratory rate; SaO2: oxygen saturation; AL: artemether
lumefantrine combination; DAT: direct antiglobulin test; IAT: indirect
antiglobulin test; DIIHA: drug-induced immune haemolytic anaemia.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KP performed the clinical assessments, obtained photographs and drafted
the manuscript and figures. RJM performed the clinical assessments,
obtained photographs and assisted in drafting the manuscript. AG was
responsible for clinical care of the patient. AG, and AMD revised the
manuscript critically for intellectual content. All authors read and approved
the final manuscript.
Acknowledgements
We thank the medical residents, attending physicians and support staff at
Chittagong Medical College Hospital for their assistance and collaboration
with the Mahidol-Oxford Tropical Medicine Research Unit (MORU) and the
staff of the malaria team at MORU who helped with data collection. Special
thanks to Dr. Rabiul Alam Md Erfanuddin and Dr. Marcus Eder for clinical as-
sistance and data collection; Dr. Katherine Chipperfield, haematopathologist
at Vancouver General Hospital, Vancouver, Canada, for reviewing the bone
marrow slides and peripheral blood smears; Dr. Neil Smith at Heartlands Hos-
pital, Birmingham, UK, for his review and advice on the haematological as-
pects of the case; and the British Columbia Center for Disease Control for
assessing the fungal microscopy images. Mahidol-Oxford Tropical Medicine
Research Unit is funded by the Wellcome Trust of Great Britain.
Author details
1Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical
Medicine, Mahidol University, 420/6 Rajvithi Road, Rajthevee, Bangkok 10400,
Thailand. 2Centre for Tropical Medicine and Global Health, Nuffield
Department of Medicine, University of Oxford, Oxford, United Kingdom.
3Department of Medicine, Chittagong Medical College Hospital, Chittagong,
Bangladesh.
Received: 30 June 2015 Accepted: 23 November 2015
References
1. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus
quinine for treatment of severe falciparum malaria: a randomised trial.
Lancet. 2005;366:717–25.
2. Camacho LH, Gordeuk VR, Wilairatana P, Pootrakul P, Brittenham GM,
Looareesuwan S. The course of anaemia after the treatment of acute,
falciparum malaria. Ann Trop Med Parasitol. 1998;92:525–37.
3. Wilson AP, Wright S, Bellingan G. Disseminated fungal infection following
falciparum malaria. J Infect. 2000;40:202–4.
4. Adner MM, Altstatt LB, Conrad ME. Coombs’-positive hemolytic disease in
malaria. Ann Intern Med. 1968;68:33–8.
5. Ritter K, Kuhlencord A, Thomssen R, Bommer W. Prolonged haemolytic
anaemia in malaria and autoantibodies against triosephosphate isomerase.
Lancet. 1993;342:1333–4.
6. Dasari P, Fries A, Heber SD, Salama A, Blau IW, Lingelbach K, et al. Malarial
anemia: digestive vacuole of Plasmodium falciparum mediates complement
deposition on bystander cells to provoke hemophagocytosis. Med Microbiol
Immunol. 2014;203:383–93.
7. Layez C, Nogueira P, Combes V, Costa FT, Juhan-Vague I, da Silva LH, et al.
Plasmodium falciparum rhoptry protein RSP2 triggers destruction of the
erythroid lineage. Blood. 2005;106:3632–8.
8. Omodeo-Sale F, Motti A, Dondorp A, White NJ, Taramelli D. Destabilisation
and subsequent lysis of human erythrocytes induced by Plasmodium
falciparum haem products. Eur J Haematol. 2005;74:324–32.
9. Silamut K, Phu NH, Whitty C, Turner GD, Louwrier K, Mai NT, et al. A
quantitative analysis of the microvascular sequestration of malaria parasites
in the human brain. Am J Pathol. 1999;155:395–410.
10. Center for Disease Control and Prevention (CDC). Published reports of
delayed hemolytic anemia after treatment with artesunate for severe
malaria–worldwide, 2010-2012. MMWR Morb Mortal Wkly Rep. 2013;62:5–8.
11. Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, Bierman WF, Clerinx J,
van Veldhuizen CK, et al. Treatment outcome of intravenous artesunate in
patients with severe malaria in the Netherlands and Belgium. Malar J. 2012;
11:102.
12. Rolling T, Schmiedel S, Wichmann D, Wittkopf D, Burchard GD, Cramer JP.
Post-treatment haemolysis in severe imported malaria after intravenous
artesunate: case report of three patients with hyperparasitaemia. Malar J.
2012;11:169.
13. Rolling T, Wichmann D, Schmiedel S, Burchard GD, Kluge S, Cramer JP.
Artesunate versus quinine in the treatment of severe imported malaria:
comparative analysis of adverse events focussing on delayed haemolysis.
Malar J. 2013;12:241.
14. Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, et al.
Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect
Dis. 2011;17:771–7.
15. Arguin PM. Case definition: postartemisinin delayed hemolysis. Blood. 2014;
124:157–8.
16. Itoda I, Yasunami T, Kikuchi K, Yamaura H, Totsuka K, Yoshinaga K, et al.
Severe falciparum malaria with prolonged hemolytic anemia after successful
treatment with intravenous artesunate. Kansenshogaku Zasshi. 2002;76:600–3.
17. Jaureguiberry S, Thellier M, Ndour PA, Ader F, Roussel C, Sonneville R, et al.
Delayed-onset hemolytic anemia in patients with travel-associated severe
malaria treated with artesunate, France, 2011-2013. Emerg Infect Dis. 2015;
21:804–12.
18. Kano S. Artemisinin-based combination therapies and their introduction in
Japan. J Infect Chemother. 2010;16:375–82.
19. Medicines for malaria venture (MMV). Experts Group Meeting on delayed
anaemia following treatment with injectable artesunate, Wien Austria. 2013.
http://www.mmv.org/sites/default/files/uploads/docs/events/2013/Injectable
ArtesunateExpertGroupMeeting.pdf.
20. Jaureguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, et al.
Postartesunate delayed hemolysis is a predictable event related to the
lifesaving effect of artemisinins. Blood. 2014;124:167–75.
21. Ashiru JO, Akang EE. Cryptococcal meningitis with malaria. A case report.
Mycopathologia. 1994;127:15–7.
22. Dabritz J, Schneider M, Just-Nuebling G, Groll AH. Minireview: Invasive
fungal infection complicating acute Plasmodium falciparum malaria.
Mycoses. 2011;54:311–7.
Plewes et al. BMC Infectious Diseases  (2015) 15:555 Page 7 of 8
23. Eckerle I, Ebinger D, Gotthardt D, Eberhardt R, Schnabel PA, Stremmel W,
et al. Invasive Aspergillus fumigatus infection after Plasmodium falciparum
malaria in an immuno-competent host: case report and review of
literature. Malar J. 2009;8:167.
24. Hocqueloux L, Bruneel F, Pages CL, Vachon F. Fatal invasive aspergillosis
complicating severe Plasmodium falciparum malaria. Clin Infect Dis. 2000;30:
940–2.
25. Mirdha BR, Sarkar T, Banerjee U, Sethi S, Dan G, Xess I. Concurrent
cryptococcal meningitis and falciparum malaria in a child with nephrotic
syndrome. Indian Pediatr. 1998;35:360–3.
26. Ruhnke M, Eichenauer E, Searle J, Lippek F. Fulminant tracheobronchial and
pulmonary aspergillosis complicating imported Plasmodium falciparum
malaria in an apparently immunocompetent woman. Clin Infect Dis. 2000;
30:938–40.
27. Soesan M, Kager PA, Leverstein-van Hall MA, van Lieshout JJ. Coincidental
severe Plasmodium falciparum infection and disseminated candidiasis. Trans
R Soc Trop Med Hyg. 1993;87:288–9.
28. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele
RL, et al. Epidemiology and outcome of zygomycosis: a review of 929
reported cases. Clin Infect Dis. 2005;41:634–53.
29. Tran TH, Day NP, Ly VC, Nguyen TH, Pham PL, Nguyen HP, et al. Blackwater
fever in southern Vietnam: a prospective descriptive study of 50 cases. Clin
Infect Dis. 1996;23:1274–81.
30. Garratty G. Drug-induced immune hemolytic anemia. Hematology. 2009;73–9.
31. Garratty G, Arndt PA. An update on drug-induced immune hemolytic
anemia. Immunohematol. 2007;23:105–19.
32. World Health Organization. Guidelines for the Treatment of Malaria. 2nd
Edition. 2010.
33. Garratty G. Immune hemolytic anemia associated with drug therapy. Blood
Rev. 2010;24:143–50.
34. Leger RM, Arndt PA, Garratty G. A negative or very weakly positive DAT
should not exclude investigation of drug-induced immune hemolytic
anemia. Transfusion. 2003;2003:11.
35. Tran TH, Day NP, Nguyen HP, Nguyen TH, Pham PL, Dinh XS, et al. A
controlled trial of artemether or quinine in Vietnamese adults with severe
falciparum malaria. N Engl J Med. 1996;335:76–83.
36. Mooney JE, Wanger A. Mucormycosis of the gastrointestinal tract in
children: report of a case and review of the literature. Pediatr Infect Dis J.
1993;12:872–6.
37. Prabhu RM, Patel R. Mucormycosis and entomophthoramycosis: a review of
the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect.
2004;10 Suppl 1:31–47.
38. Cohen SG, Greenberg MS. Rhinomaxillary mucormycosis in a kidney
transplant patient. Oral Surg Oral Med Oral Pathol. 1980;50:33–8.
39. Doni BR, Peerapur BV, Thotappa LH, Hippargi SB. Sequence of oral
manifestations in rhino-maxillary mucormycosis. Indian J Dent Res. 2011;22:
331–5.
40. Dasari P, Reiss K, Lingelbach K, Baumeister S, Lucius R, Udomsangpetch R,
et al. Digestive vacuoles of Plasmodium falciparum are selectively
phagocytosed by and impair killing function of polymorphonuclear
leukocytes. Blood. 2011;118:4946–56.
41. Cunnington AJ, Njie M, Correa S, Takem EN, Riley EM, Walther M. Prolonged
neutrophil dysfunction after Plasmodium falciparum malaria is related to
hemolysis and heme oxygenase-1 induction. J Immunol. 2012;189:5336–46.
42. Abe F, Inaba H, Katoh T, Hotchi M. Effects of iron and desferrioxamine on
Rhizopus infection. Mycopathologia. 1990;110:87–91.
43. McNab AA, McKelvie P. Iron overload is a risk factor for zygomycosis. Arch
Ophthalmol. 1997;115:919–21.
44. Eisen DP, Robson J. Complete resolution of pulmonary Rhizopus oryzae
infection with itraconazole treatment: more evidence of the utility of azoles
for zygomycosis. Mycoses. 2004;47:159–62.
45. Quinio D, Karam A, Leroy JP, Moal MC, Bourbigot B, Masure O, et al.
Zygomycosis caused by Cunninghamella bertholletiae in a kidney transplant
recipient. Med Mycol. 2004;42:177–80.
46. Krishnan PA. Fungal infections of the oral mucosa. Indian J Dent Res. 2012;
23:650–9.
47. Munoz-Corcuera M, Esparza-Gomez G, Gonzalez-Moles MA, Bascones-
Martinez A. Oral ulcers: clinical aspects. A tool for dermatologists. Part II.
Chronic ulcers. Clin Exp Dermatol. 2009;34:456–61.
48. Munoz-Corcuera M, Esparza-Gomez G, Gonzalez-Moles MA, Bascones-
Martinez A. Oral ulcers: clinical aspects. A tool for dermatologists. Part I.
Acute ulcers. Clin Exp Dermatol. 2009;34:289–94.
49. Muzyka BC, Epifanio RN. Update on oral fungal infections. Dent Clin North
Am. 2013;57:561–81.
50. Hoffman SL, Rustama D, Punjabi NH, Surampaet B, Sanjaya B, Dimpudus AJ,
et al. High-dose dexamethasone in quinine-treated patients with cerebral
malaria: a double-blind, placebo-controlled trial. J Infect Dis. 1988;158:325–31.
51. Warrell DA, Looareesuwan S, Warrell MJ, Kasemsarn P, Intaraprasert R,
Bunnag D, et al. Dexamethasone proves deleterious in cerebral malaria. A
double-blind trial in 100 comatose patients. N Engl J Med. 1982;306:313–9.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Plewes et al. BMC Infectious Diseases  (2015) 15:555 Page 8 of 8
